Infantile hemangioma (IH) is the most common benign tumor of childhood, with a prevalence of 4 % to 10 %. It is characterized by a proliferative rapid growth phase, which starts after a few weeks of life, followed by a slow regression phase. In IH cases that are potentially disfiguring or life-threatening (10 % to 15 % of all cases), systemic therapy should be promptly initiated. Data source: The present study reviews published scientific articles available in reliable electronic databases. Selected were all studies that evaluated the pathogenesis of IH and the mechanisms of action of propranolol. Conclusions: The pathogenesis of IH has not been fully elucidated. Studies show that, in the proliferative phase of IH, there is an imbalance of angiogenic factors and an increase in the levels of vascular endothelial growth factor and matrix metalloproteinases 2 and 9. In the regression phase, the levels of these factors decrease, whereas those of antiangiogenic factors, including tissue inhibitors of matrix metalloproteinases, increase. Since 2008, propranolol has become the drug of choice in the treatment of IH, targeting vascular tone, angiogenesis, and apoptosis. Current insights into the pathogenesis of IH allow for the development of new therapeutic strategies.
Introduction
Infantile hemangioma (IH) is the most common benign tumor of childhood, with a prevalence of 4 % to 10 % in children. The incidence is higher in females, Caucasians, premature newborns, low-weight neonates, and twins [1] [2] [3] [4] [5] . Infantile hemangioma primarily occurs on the face and neck (80 % of cases) but also on the trunk and extremities [ 4 ] . Although usually absent at birth, precursor lesions in the form of telangiectases or erythematous macules may be found in 30 % to 50 % of cases [ 4 ] .
Following the fi rst few weeks of life, a proliferative rapid growth phase sets in until the age of 8 to 12 months of age [ 6 ] . The evolution of IH is usually benign, and followed by a slow regression phase until the age of 5 to 10 years [ 7 ] . In cases of IH that are potentially disfi guring or life-threatening (10 % to 15 % of all cases), systemic therapy should be promptly initiated. Other indications for systemic therapy take into account existing or imminent functional impairment, ulceration, pain, and bleeding as well as the risk of long-term or permanent disfi gurement. "Life-threatening lesions include obstructing IHs of the airway. Pain and bleeding are examples of urgent sequelae that occur as a result of ulceration. Other examples of functional impairment include ocular impairment (loss of visual axis leading to deprivation amblyopia, astigmatism, strabismus, visual fi eld cuts) and impaired feeding because of involvement of the lips or mouth. Long-term and permanent disfi gurement is a concern with IHs of certain anatomic sites (eyelid, nasal tip, lip, breast, genitalia) and with severe ulceration, because these will ultimately leave a scar of similar size" [ 20 ] .
The pathogenesis of IH has not yet been fully elucidated. Studies have shown that in the proliferative phase, there is an imbalance of angiogenic factors and an increase in the levels of vascular endothelial growth factor (VEGF), basic growth factor of fi broblasts (bFGF), and matrix metalloproteinases (MMPs) 2 and 9 [11] [12] [13] . In the regression phase, the levels of these factors decrease, whereas those of antiangiogenic factors, including tissue inhibitors of metalloproteinases (TIMP), increase [ 14, 15 ] .
New alternatives for the treatment of IH have emerged in recent years. Prior to 2008, complicated cases of IH had been treated with systemic corticosteroids, vincristine, interferon, and cyclophosphamide. However, these drugs have several restrictions on their use and are associated with severe side effects [ 10, 16 ] . In 2008, Léauté-Labrèze et al. [ 17 ] reported the use of propranolol for the treatment of IH. Since then, this agent has been considered the drug of fi rst choice.
Other treatment modalities, including pulsed dye laser treatment, can be combined with drug therapy, and may, in some cases, be indicated for residual lesions and management of persisting postinvolution telangiectasia after discontinuation of the medication [ 18, 19 ] .
During involution, surgery may be indicated for excision of residual fi brofatty tissue, resection of scarred/excess skin, and/or reconstruction of damaged structures. Timing of surgery is based on the age of the patient, the location and degree of deformity, and whether the tumor is still regressing [ 20 ] .
Several mechanisms of action of beta-blockers are involved in the treatment of IH. Vasoconstriction decreases the blood supply to the lesion due to the action of beta-adrenergic receptors present on the endothelial cells of IH. Moreover, beta-blockers inhibit angiogenesis by decreasing the expression of VEGF, bFGF, MMP-2, and MMP-9 and by inducing apoptosis of endothelial cells in IH [ 12, [21] [22] [23] [24] .
Pathogenesis of infantile hemangioma
The pathogenesis of IH has not been fully elucidated. It is postulated that IH is formed by the proliferation of immature endothelial cells stimulated by angiogenic factors. Cytokines and growth factors induce the formation of a capillary network by endothelial cells. The most extensively studied cytokines involved in the growth of IH are VEGF, b-FGF, MMP-2, and MMP-9.
The detection of stem cell markers in IH indicates the recruitment of these cells to the lesion, where they differentiate into three cell types: endothelial cells, pericytes, and adipocytes [ 25 ] .
The presence of endothelial progenitor cells suggests the early origin of IH. Studies conducted on the endothelium in proliferative IH have reported the expression of early mesoderm markers, resulting in the formation of adipose and fi brous tissue in regressing lesions [ 25, 26 ] The review by Itinteang and Bischoff [ 12 ] on the biology of IH mentions the hypothesis of a placental embolic origin early on during fetal development and a favorable postnatal environment. VEGF promotes the proliferation and differentiation of primitive cells that are embolized for the formation of IH.
The understanding of the mechanism of vascular formation in IH is essential for the development of new drugs and treatment strategies.
Vascular endothelial growth factor
VEGF is a protein involved in vascular proliferation and permeability [ 27 ] . One of the most potent angiogenic factors, it is produced by various cells including endothelial cells, macrophages, platelets, and tumor cells. VEGF stimulates the migration of vascular endothelial cells, the proliferation and formation of new vessels, and the inhibition of apoptosis [ 28 ] .
During fetal development, the microenvironment may be an important factor in vessel formation. Hypoxia triggers the production of hypoxia-inducible factor 1-alpha (HIF-1 α ), which induces transcription of the VEGF gene, which in turn stimulates the proliferation and migration of endothelial progenitor cells. This results in the formation of new vessels [ 15, 29 ] and the synthesis of proteinases (metalloproteinases) involved in the reorganization of the extracellular matrix [ 15, 30 ] .
VEGF expression can be detected in tissue, blood, and urine samples. Several studies have reported an increase in the expression of VEGF during the proliferative phase of IH. In the regression phase, the expression of TIMP increases, whereas the expression of VEGF decreases [ 29, 31, 32 ] . A number of studies have investigated the increase in VEGF serum levels in patients with IH [ 15, 29, 33, 34 ] .
Using in situ hybridization, a study of endothelial cells during the proliferative phase of IH showed an increase in the expression of VEGF and bFGF, whereas the expression of these markers decreased during the regression phase [ 35 ] .
By means of enzyme-linked immunosorbent assay (ELI-SA), Zhang et al. (2005) [ 34 ] examined circulating VEGF levels in blood samples of 59 patients with proliferative IH, including 38 patients with IH in regression, 18 patients with vascular malformation, and 12 healthy controls. While VEGF levels were found to be elevated in the proliferative phase of IH, there were no signifi cant differences between the other three study groups. The authors suggested that serum VEGF levels might be useful in staging IH lesions. The results described in that report possibly provide an objective basis for distinguishing proliferating IH from vascular malformation, and may refl ect an angiogenic pattern of hemangioma progression and involution.
Przewrati, Sitkiewicz, and Andrzejewska (2010) [ 33 ] determined VEGF levels in peripheral blood and tumor samples taken from 52 children with IH and 14 children with vascular malformations, as well as in the peripheral blood of 36 controls. Serum levels of VEGF, as determined by ELI-SA, were similar between the three groups. However, serum VEGF levels in children with proliferative IH was signifi cantly higher than those in children with regressing IH, vascular malformations, and in healthy controls. In addition, VEGF levels in the tumor samples were higher than those in the peripheral blood samples. The authors concluded that VEGF serum levels were elevated in IH but not in individuals with vascular malformations or healthy individuals.
According to published fi ndings [ 33, 34 ] , elevated VEGF serum levels in children with proliferating IH are consistent with the initial hypothesis of increased activity of this cytokine in such lesions, and may provide more insight into the pathogenesis of IH.
In addition to looking at VEGF levels in IH patients, it is possible to measure this factor in the follow-up of patients with certain types of cancers (e. g., colon and rectum, lung, breast, glioblastoma, ovarian, kidney and liver cancer) [ 36 ] . The increased VEGF levels in these patients are considered a predictive factor for the tumor stage and an indicator of the likelihood of survival [36] [37] [38] .
Matrix metalloproteinases
Matrix metalloproteinases are proteinases responsible for the degradation of the extracellular matrix and neovascularization. They are involved in the proliferation, migration, and adhesion of cells [ 39 ] . These proteins are associated with many physiological processes, including tissue remodeling, infl ammation, as well as neoplastic and vascular diseases [ 39, 40 ] . Matrix metalloproteinase levels can be measured in tissue, blood, and urine samples.
MMP-2 (gelatinase A, 72 kDa) and MMP-9 (gelatinase B, 92 kDa) degrade basement membrane collagen. Under physiological conditions, the activity of MMPs is regulated by the inhibition of TIMP-1 [ 27 ] .
Matrix metalloproteinases are secreted by tumor cells and involved in angiogenesis. The evolution of angiogenesis depends on the remodeling of the extracellular matrix in the tissue spaces around the vessels. Matrix metalloproteinases degrade components of the extracellular matrix, allowing for the formation of new vessels [ 40 ] .
Several studies have shown that hypoxia increases VEGF levels, which increases MMP levels and decreases TIMP-1 levels [ 41 ] . It is believed that the formation of the vascular network in IH is the result of the proliferation of endothelial progenitor cells. VEGF stimulates the proliferation of these cells; mobilization from the bone marrow is thought to occur by the action of MMP-9 [ 29 ] . This mechanism indicates that a treatment capable of modulating the expression of VEGF and MMP-9 may be an option for preventing growth and proliferation of IH.
Increased levels of MMP-2 and 9 have been observed in tissue, blood, and urine samples from children in the proliferative phase of IH [ 15, 30 ] . There is evidence that MMP-2 and MMP-9 are regulated by adrenergic β -receptors [ 42 ] . Marler et al. (2005) [ 14 ] measured urinary levels of MMP-2, MMP-9, VEGF, and bFGF in 217 patients (57 with IH and 160 with vascular malformations) as well as 74 controls. Using ELISA, the authors found elevated urinary levels of MMP-2, MMP-9, and bFGF in patients with IH (53 %) and lower levels in patients with vascular malformations (41 %) and in control subjects (22 %). Furthermore, the levels of MMP-2, MMP-9, and bFGF paralleled the extent and activity of the existing vascular anomalies. However, no signifi cant differences among the three groups were observed for VEGF.
The identifi cation of these proteins can explain the pathophysiological bases for these vascular disorders and may be used together with clinical markers of remission or exacerbation in response to treatment [ 14 ] . Kleinman et al. (2007) [ 15 ] evaluated the relationship between the mediators of endothelial progenitor cells and vascular tumors. Ten children with proliferative IH and ten controls were included in this study. The authors measured the levels of VEGF and MMP-9 in blood samples by ELI-SA and the levels of MMP-9, VEGF-A, and HIF-1 α in tissue samples by immunohistochemistry. The levels of these markers were increased in children with IH. As perinatal hypoxemia has been identifi ed as an important etiological factor in IH, increased production of HIF-1 α and subsequently VEGF (as has been shown in proliferating IH) appears to be a logical consequence.
Mechanism of action of beta-blockers
Propranolol is a non-cardioselective blocker of beta-adrenergic receptors but its mechanism of action in the treatment of IH has not been fully elucidated.
The catecholamines epinephrine and norepinephrine interact with the adrenergic receptors beta-1 (located in the heart and kidneys) and beta-2 (located in peripheral blood vessels, lungs, and skeletal muscle). An antagonist of these receptors, propranolol inhibits vasodilation via beta-receptors, causing vasoconstriction and reduced capillary blood fl ow in IH lesions [ 12, 21, 22 ] .
Norepinephrine stimulates HIF-1-alpha, which increases the levels of VEGF, MMP-2, and MMP-9 in tumor cells. Propranolol blocks the action of catecholamines in the cell, thus reducing the levels of VEGF and MMPs without interfering with the baseline production of cytokines by the cells [ 22, 43 ] .
The current concept of propranolol in the treatment of IH includes effects on endothelial cells, vascular tone, angiogenesis, and apoptosis. They can be classifi ed into shortterm, mid-term, and long-term effects [ 21 ] . After 1-3 days of propranolol treatment, changes in color and consistency of IH are observed due to vasoconstriction, which decreases blood fl ow to the lesion. The mid-term effects may be caused by blocking the release of proangiogenic factors (i. e., VEGF, bFGF, MMP-2, and MMP-9), thus limiting the growth of IH. The long-term effects are believed to be caused by the induction of apoptosis in endothelial cells and subsequent tumor regression [ 21, 22 ] .
The molecular analysis of endothelial cells during treatment of IH with propranolol suggests that blocking the vascular endothelial growth factor receptor-2 (VEGFR-2) decreases proliferation and migration of IH cells and induces cell apoptosis [ 24 ] .
It is believed that IH lesions originate from de novo formation of blood vessels by immature progenitor cells. Propranolol may prevent the differentiation of stem cells of IH into pericytes and endothelial cells and promote the differentiation of progenitor cells into adipocytes. This results in accelerated transition from the proliferative to the regression phase [ 22 ] .
The effects of propranolol on the proliferation and apoptosis of endothelial cells of resected hemangioma specimens was studied by Ji et al. (2012) [ 44 ] . The mechanism of action of the drug in these cells was determined by Western blot analysis and PCR. The authors demonstrated the inhibitory effects of propranolol on the viability and proliferation of endothelial cells. Apoptosis was shown to be more pronounced when these cells were treated with propranolol. Furthermore, the expression of VEGF decreased in treated cells in a dose-dependent manner. Kleber et al. (2012) [ 45 ] measured the levels of MMP-2 and MMP-9 in urine samples from 22 children with IH and 21 healthy controls (age < 1 year). The authors identifi ed the presence of MMP-2 and MMP-9 in urine samples of healthy children, and found an increase in MMP-2 levels with decreasing age. However, there was no correlation between MMP-9 levels and age and/or the clinical status of the patients. Urine MMP-2 levels in children with IH were lower than in healthy controls (p = 0.02). The markers were measured prior to treatment, two weeks after treatment, and two months after treatment. MMP-2 levels increased (p = 0.04) after two weeks of treatment, but did not change (p = 0.84) after two months of treatment.
Taking into account the above-mentioned literature, as well as the results presented by Kleber et al., the correlation between MMPs, proliferation, and regression of hemangiomas and propranolol remains unclear [ 45 ] . Chen et al. (2013) [ 46 ] evaluated the changes in VEGF levels in 22 IH patients treated with propranolol. The authors measured serum markers by ELISA and monitored changes in tumor volume by ultrasound. Measurements were conducted prior to treatment, one month after treatment, and three months after treatment. After one month and three months of treatment, the levels of VEGF decreased 21.6 % (p = 0.003) and 18 % (p = 0.63), respectively. Moreover, VEGF expression correlated with tumor size (p = 0.046) but not with age (p = 0.56). Yuan et al. (2013) [ 47 ] analyzed the effectiveness of propranolol treatment and the changes in serum levels of VEGF and endothelial nitric oxide synthase (eNOS) in 35 patients with proliferative IH. The authors assessed clinical improvement by physical examination and ultrasound; serum levels were determined by ELISA. There was a positive response to treatment, and a signifi cant decrease in VEGF and eNOS levels was observed from the second month of treatment. It is well documented that eNOS plays an important role in vasodilatation; propranolol inhibits the activation of eNOS, thus leading to vasoconstriction. The authors speculated that the effects of propranolol on IH might be due to the reduction of VEGF and eNOS. Wu et al. (2015) [ 48 ] investigated the effectiveness of propranolol treatment in IH and changes in the serum levels of VEGF, bFGF, and MMP-9. The authors examined 129 cases, 97 of which were treated with oral propranolol; 32 received no treatment. ELISA was used to measure marker levels prior to treatment initiation and then again -in 40 children in the treatment group -after eight weeks of treatment. Marker levels were not measured in the untreated group. There was a remarkable improvement of IH in the treated group. In addition, there was a signifi cant reduction in VEGF, bFGF, and MMP-9 after eight weeks of treatment. Based on these fi ndings, the mechanism underlying the effects of propranolol may be associated with the downregulation of VEGF, bFGF, and MMP-9.
Conclusions
Infantile hemangioma is the most common benign tumor in children. Since the introduction of propranolol in the treatment of complicated IH cases in 2008, many studies have been conducted on the pathogenesis and treatment of IH, highlighting the characteristics with respect to the various stages of tumor evolution and allowing for the development of novel therapeutic strategies.
However, the pathogenesis of IH has not yet been fully elucidated. Studies have shown that the levels of angiogenic factors such as VEGF, MMP-2, and MMP-9 increase in the proliferative phase of IH. By contrast, in the regression phase, the levels of these factors decrease, whereas those of antiangiogenic factors -including tissue inhibitors of matrixmetalloproteinases -increase. The mechanisms of action of propranolol in the treatment of IH seem to include a reduction in the levels of angiogenic factors as well as vasoconstriction and induction of cell apoptosis.
